Diverging paths, difficult choices. Winter 2012By Dr Steve Arlington and Dr Nick Davies Pharma is poised on a knife-edge. Major scientific and technological advances, together with socio-demographic changes, rising demand for medicines and trade liberalisation, will revive i...
|
Asian innovation: a unique opportunity for the pharmaceutical industry. Fall 12By Dr Yi Gu and William Shi As the third-largest market for the pharmaceutical industry, the China/Asia region is becoming increasingly important. The AstraZeneca Innovation Center China (ICC) in Shanghai is perfect...
|
The challenges of the changing drug discovery model. Fall 12By Dr Mark Downs and Dr Tom Blackburn The drug development industry is restructuring worldwide. This brings different ways of working and new challenges. As the industry moves away from internally focused research to an exter...
|
Innovate while derisking drug development: yes we can! Summer 12Taher Abbasi, Pradeep Fernandes, Dr Shireen Vali and Professor Gurkirpal Singh The outlook for the drug industry continues to remain bleak in context of productivity and success rates. In spite of ongoing increase in R&D expenses and technology revolutions in the ge...
|
A life sciences powerhouse: Ontario, Canada's story. Spring 12By Michael Stewart Around the world, competition between life sciences companies is fierce. And so is the competition between jurisdictions wanting to attract the good paying jobs, innovative spirit and R&D...
|
From outsourced to open: the continuing evolution of the drug discovery business model. Spring 12Dr Mary Canady One doesn't have to look far to find that the large pharmaceutical business model has many market forces working against it, such as patent expirations, dwindling pipelines, and reduced R...
|
|
|
